BeOne Medicines Ltd. (ONC) Latest Company News

Oct 24, 2026, 08:15 UTC
BeOne Medicines announced new data from multiple investigational medicines across gastrointestinal, lung and breast cancers at the ESMO 2026 Congress.
Source:
- businesswire.com
Oct 23, 2026, 14:15 UTC
BeOne Medicines announced survival results from the planned second interim and final formal analyses of its Phase 3 Jazz Pharmaceuticals plc trial, reporting sustained survival benefit for TEVIMBRA plus ZIIHERA and chemotherapy as first-line treatment for HER2-positive gastroesophageal cancer.
Source:
- businesswire.com
Oct 22, 2026, 10:01 UTC
BeOne Medicines Ltd. said it will report its third-quarter 2026 financial results before markets open on November 5, 2026, and host a management webcast at 8:00 a.m. ET.
Source:
- businesswire.com
Oct 21, 2026, 04:12 UTC
Hong Kong's Hang Seng Index fell 83 points, or 0.3%, to 23,784 at the half-day close; the Hang Seng Tech Index fell 30 points, or 0.8%, to 4,015, and the Hang Seng China Enterprises Index fell 41 points, or 0.5%, to 7,988.
Source:
- aastocks.com
Oct 21, 2026, 04:12 UTC
Hong Kong-listed stocks showed mixed moves at the half-day close, with Contemporary Amperex Technology falling 10.1% and Bright Future Technology and Crystal International reaching record highs.
Source:
- aastocks.com
Oct 6, 2026, 10:30 UTC
BeOne Medicines completed negotiations with the pan-Canadian Pharmaceutical Alliance for TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Source:
- standard-freeholder.com
Oct 5, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 5, 2026, with the Hang Seng Index up 68 points (0.3%) at 24,040, the Hang Seng Tech Index up 25 points (0.6%) at 4,183, and the China Enterprises Index up 21 points (0.3%) at 8,051 on turnover of HK$98.102 billion.
Source:
- aastocks.com
- aastocks.com
Oct 5, 2026, 01:32 UTC
Hong Kong stocks opened slightly lower on Monday, with the Hang Seng Index down 8.88 points at 23,963.41, the Hang Seng Tech Index down 0.47% at 4,138.38 and the China Enterprises Index down 0.12% at 8,021.07.
Source:
Oct 2, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.
Source:
Oct 2, 2026, 01:30 UTC
Hong Kong stocks opened sharply lower on the first trading day of October, with the Hang Seng Index gapping down 513.54 points (2.09%), the Hang Seng Tech Index falling 1.81% to 4176.92 and the China Enterprises Index dropping 1.72% to 8078.49, led by HSBC Holdings down 5.51% and AIA down 4.21%.
Source:
Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Source:
Aug 31, 2026, 19:00 UTC
BeOne Medicines announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients and strengthen its U.S. manufacturing footprint.
Source:
- businesswire.com
Aug 18, 2026, 10:00 UTC
BeOne Medicines, BeOne Care Foundation, and The Max Foundation renewed their partnership through 2028 to expand access to BRUKINSA for chronic lymphocytic leukemia treatment in low- and middle-income countries.
Source:
- businesswire.com
Aug 10, 2026, 10:00 UTC
BeOne Medicines and Revolution Medicines announced a multi-part collaboration including clinical development and regional commercialization of drug combinations.
Source:
Aug 5, 2026, 12:07 UTC
BeiGene's new drug Baiyueda (sonrotoclax) received accelerated approval from the US FDA for treating adult patients with relapsed or refractory mantle cell lymphoma.
Source:
- yicai.com
Aug 5, 2026, 12:07 UTC
BeiGene reported H1 2026 results with net profit of 3.271 billion yuan, up 6.27 times year-on-year, and revenue of 22.22 billion yuan, up 26.8% year-on-year.
Source:
Aug 5, 2026, 00:00 UTC
BeOne Medicines Ltd. reported Q2 2026 financial results with total revenue of $1.705 billion, GAAP diluted EPS of $2.05, and non-GAAP diluted EPS of $3.84.
Source:
Jun 30, 2026, 10:00 UTC
BeOne Medicines announced positive Phase 3 results for BRUKINSA in frontline mantle cell lymphoma from the MANGROVE study.
Source:
- businesswire.com

ONC

BeOne Medicines announced new data from multiple investigational medicines across gastrointestinal, lung and breast cancers at the ESMO 2026 Congress.

BeOne Medicines announced survival results from the planned second interim and final formal analyses of its Phase 3 Jazz Pharmaceuticals plc trial, reporting sustained survival benefit for TEVIMBRA plus ZIIHERA and chemotherapy as first-line treatment for HER2-positive gastroesophageal cancer.

BeOne Medicines Ltd. said it will report its third-quarter 2026 financial results before markets open on November 5, 2026, and host a management webcast at 8:00 a.m. ET.

Hong Kong's Hang Seng Index fell 83 points, or 0.3%, to 23,784 at the half-day close; the Hang Seng Tech Index fell 30 points, or 0.8%, to 4,015, and the Hang Seng China Enterprises Index fell 41 points, or 0.5%, to 7,988.

Hong Kong-listed stocks showed mixed moves at the half-day close, with Contemporary Amperex Technology falling 10.1% and Bright Future Technology and Crystal International reaching record highs.

BeOne Medicines completed negotiations with the pan-Canadian Pharmaceutical Alliance for TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Hong Kong stocks closed higher on October 5, 2026, with the Hang Seng Index up 68 points (0.3%) at 24,040, the Hang Seng Tech Index up 25 points (0.6%) at 4,183, and the China Enterprises Index up 21 points (0.3%) at 8,051 on turnover of HK$98.102 billion.

Hong Kong stocks opened slightly lower on Monday, with the Hang Seng Index down 8.88 points at 23,963.41, the Hang Seng Tech Index down 0.47% at 4,138.38 and the China Enterprises Index down 0.12% at 8,021.07.

Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.

Hong Kong stocks opened sharply lower on the first trading day of October, with the Hang Seng Index gapping down 513.54 points (2.09%), the Hang Seng Tech Index falling 1.81% to 4176.92 and the China Enterprises Index dropping 1.72% to 8078.49, led by HSBC Holdings down 5.51% and AIA down 4.21%.

President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.

BeOne Medicines announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients and strengthen its U.S. manufacturing footprint.

BeOne Medicines, BeOne Care Foundation, and The Max Foundation renewed their partnership through 2028 to expand access to BRUKINSA for chronic lymphocytic leukemia treatment in low- and middle-income countries.

BeOne Medicines and Revolution Medicines announced a multi-part collaboration including clinical development and regional commercialization of drug combinations.

BeiGene's new drug Baiyueda (sonrotoclax) received accelerated approval from the US FDA for treating adult patients with relapsed or refractory mantle cell lymphoma.

BeiGene reported H1 2026 results with net profit of 3.271 billion yuan, up 6.27 times year-on-year, and revenue of 22.22 billion yuan, up 26.8% year-on-year.

BeOne Medicines Ltd. reported Q2 2026 financial results with total revenue of $1.705 billion, GAAP diluted EPS of $2.05, and non-GAAP diluted EPS of $3.84.

BeOne Medicines announced positive Phase 3 results for BRUKINSA in frontline mantle cell lymphoma from the MANGROVE study.